Hemostemix Inc. (CVE:HEM – Get Free Report) dropped 13.9% during mid-day trading on Wednesday . The company traded as low as C$0.14 and last traded at C$0.16. Approximately 295,053 shares changed hands during trading, a decline of 43% from the average daily volume of 519,469 shares. The stock had previously closed at C$0.18.
Hemostemix Price Performance
The stock has a market capitalization of C$21.13 million, a PE ratio of -4.23 and a beta of 0.20. The company’s 50 day simple moving average is C$0.19 and its 200 day simple moving average is C$0.12. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- What is a Secondary Public Offering? What Investors Need to Know
- Nebius Group: NVIDIA’s Investment Sparks All-Time Highs
- The Role Economic Reports Play in a Successful Investment Strategy
- SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It?
- What is a Stock Market Index and How Do You Use Them?
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
